Santa Monica, CA and Salt Lake City, Utah, April. 20th, 2016 – PRBuzz – Leonhardt Ventures — a developer, manufacturer and marketer of advanced organ regeneration products — has announced the expansion of its intellectual property portfolio via its startup OrthodontiCell. OrthodontiCell is incubating within Cal-X Stars Business Accelerator, Inc. The Company has filed a provisional patent application in the U.S. Patent and Trademark Office for inventions relating to bioelectric stimulation controlled release of RANKL and a number of other proteins, including stem cell homing factor SDF-1, designed to accelerate tooth movement and cut in half the time required for orthodontic treatment with braces and clear aligners – the OrthodontiCell Tooth Movement Accelerator TM. Studies are currently underway in Argentina.
Howard J. Leonhardt the Founder and CEO of Leonhardt, Ventures and Cal-X Stars Business Accelerator, Inc., Dr. John Marchetto an Orthodontist in Weston, Florida and Dr. Jorge Genovese a collaborative researcher from Buenos Aires, Argentina are co-inventors of this product.
“This invention addresses the desire to reduce in half the time it takes to treat orthodontic patients. The approach is to speed up the normal process of bone demineralization in order to accelerate tooth movement. Millions of people that wear braces or aligners would love to cut their treatment time in half. Other light and vibration devices fall short in providing a clear and reliable pathway to the underlying mechanism of action for tooth movement. Also, the repeat RANKL needle injection methods are painful for the patients and are needed too frequently. This invention is completely different than previous devices as it provides clear cut direct control for the release of essential cells and proteins needed for accelerating tooth movement, and with less pain”, states Dr. John Marchetto, co-Inventor.
The OrthodontiCell team is in the process of launching well-designed studies both in and outside the U.S. to document the safety and efficacy of its Tooth Movement Accelerator TM product.
Howard Leonhardt co-inventor of this device previously patented an electrical stimulation device for recruiting stem cells to damaged organs including the heart by causing the release of SDF-1 stromal derived factor-1 on demand working in collaboration with Dr. Juan Chachques of Paris – http://www.google.com/patents/US20050171578. Dr. Genovese has been conducting electrical stimulation based regeneration research for over twenty years with numerous published peer reviewed papers and is co-inventor with Leonhardt on nearly a dozen new patents pending.
Howard Leonhardt presented earlier this year their team’s 27 Year Experience with Stem Cell Therapies for Organ Regeneration and highlighted some of the spin out startup technology platforms that have emerged from the original work on heart regeneration which are now also incubating in the Cal-X Stars Business Accelerator and Leonhardt’s Launchpads – http://mysocialgoodnews.com/howard-leonhardt-to-present-27-years-of-experience-with-stem-cell-therapies-at-academy-of-regenerative-practices-winter-conference-and-scientific-seminar/
About Leonhardt Ventures: Since 1982 Leonhardt Ventures (formerly H.J. Leonhardt & Co.) has been developing and bringing to market cardiovascular products. Howard Leonhardt founder has 21 issued U.S. patents with over 100 U.S. patent claims and has about a dozen more pending or in process. Leading past products include the POLY-CATH line of predictably compliant balloon catheters, TALENT stent graft, VALVE STENT percutaneous heart valve, MyoCath and Pro-Cell Stem Cell Delivery Catheters, BioPace biological pacemaker, Stem Cell Bra and the BioLeonhardt micro stimulator and micro pump for heart regeneration – www.leonhardtventures.com
About Cal-X Stars Business Accelerator, Inc.: Formed in 2012 Cal-X Stars is a 5 year business accelerator focused on regenerative medtech and regenerative economy startups. Cal-X Stars Business Accelerator, Inc. helps support and operate Leonhardt’s Launchpads NorCal, CalXelerator, SciAcclerator, Leonhardt’s Launchpads Utah, LABioHub and Startup California – www.calxstars.com
About OrthodontiCell: A startup focused on accelerating tooth movement formed in 2015 by Dr. John Marchetto and Howard Leonhardt incubating within the Cal-X Stars Business Accelerator. A spin out of previously formed DentaCell.
About DentaCell: A startup focused on reducing pain and accelerating healing of gums after dental procedures and on tooth pulp cold storage for later stem cell retrieval and expansion founded incubating with the Cal-X Stars Business Accelerator – https://leonhardtventures.com/dentacell/
All capital for OrthodontiCell (a high risk early stage startup) is raised only through Cal-X Stars Business Accelerator, Inc via 506D Part C – SEE RISK FACTORS HERE >http://calxstars.com/investor-relations/ limited to accredited and sophisticated investors only or Leonhardt Ventures’s own internal funds at this time. Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. are incubating 23 regenerative medtech startups at this time most of them based on the same patented micro stimulator and micro pump combination device pointed to different organs – BioLeonhardt MyoStim = heart, MyoStim Peripheral = limbs, CerebraCell = brain, EyeCell = eye, AortaCell = aortas, PancreaCell = pancreas, Stem Cell Bra = breast, RegenaLung = lungs, HairCell = hair, Valvublator = heart valves, BioPace = biological pacemaker.
Leonhardt Ventures’ Cal-X Stars Business Accelerator is led by over 70 business mentors and team members with substantial industry experience – http://calxstars.com/team-cal-x/and over 35 scientists and clinicians on our Scientific Advisory Board – http://calxstars.com/scientific-advisory-board/
Contact: OrthodontiCell a Cal-X Stars Business Accelerator, Inc. Startup Technology Platform – Media Relations Brian Hardy @ email@example.com or Howard Leonhardt @ firstname.lastname@example.org.
This provisional patent application was filed electronically utilizing www.legalzoom.com software.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the “safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “proposes” or “planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” “would,” “could” and similar expressions or the negative versions thereof and which also may be identified by their context, such as references to “products under development”. All statements that address operating performance or events or developments that Cal-X Stars Business Accelerator, Inc. or any of its incubating startups such as BioLeonhardt MyoStim, DentalCell or OrthdontiCell, expects or anticipates will occur in the future are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, we operate in a complex and changing domestic and international competitive environment where new and unanticipated risks may arise, and consequently the information on which such expectations were based, such as expectations of distributor product placements and sales, timing of planned and anticipated product deliveries or product introductions, may change. Forward-looking statements involve inherent very high risks and multiple uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in the Risk Factors and in Management’s Discussion of the Company’s filed Private Placement Memorandum. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. The information shared communicates our intent of direction but does not imply in any form that any required agreements, patents are locked secure in place. All our incubating startups are under funded and under staffed and we are bootstrapping to make progress with limited resources. We are at even greater risk due to our business plan of bringing multiple startups forward simultaneously with a small core staff spread thin. Cal-X Stars Business Accelerator, Inc. incubates early stage startups and technology platforms focused on regenerative medtech and regenerative economy innovations. By nature these early stage startups are high risk investments compounded in risk by requiring many years to get to market through clinical trials and multiple collaborative agreements which are not yet secured. This investment is only suitable to sophisticated and accredited investors prepared to lose all of their investment understanding clearly the very high risk.